POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy fights dangerous virus after transplant
Disease control Recruiting nowThis study tests a new treatment for Epstein-Barr virus (EBV) infection that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and attack the virus. About 18 adults who have EBV in their blood after a transplant…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 17, 2026 01:47 UTC
-
New cell therapy targets EBV after transplant: early trial shows promise
Disease control Recruiting nowThis study is for people who have had a stem cell transplant and later develop a high level of EBV virus in their blood. The treatment uses special immune cells (EBV-AST cells) to fight the virus. The main goals are to find the safest dose and see if it can clear the virus. About…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New targeted therapy shows promise for Tough-to-Treat lymphomas
Disease control Recruiting nowThis study tests a drug called loncastuximab tesirine in adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug works like a smart bomb, attaching to a marker on cancer cells and delivering chemotherapy directly to them. The main goal is to …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
New hope for transplant patients: targeted combo may replace harsh chemo
Disease control Recruiting nowThis study tests a two-drug combination (polatuzumab vedotin plus rituximab) as a first treatment for a rare blood cancer that can occur after an organ or stem cell transplant. About 12 adults who have not had prior therapy will receive the drugs to see if the combo is safe and w…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC